Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

PURPOSE: Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. PATIENT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Piekarz, Richard L., Frye, Robin, Turner, Maria, Wright, John J., Allen, Steven L., Kirschbaum, Mark H., Zain, Jasmine, Prince, H. Miles, Leonard, John P., Geskin, Larisa J., Reeder, Craig, Joske, David, Figg, William D., Gardner, Erin R., Steinberg, Seth M., Jaffe, Elaine S., Stetler-Stevenson, Maryalice, Lade, Stephen, Fojo, A. Tito, Bates, Susan E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2773225/
https://ncbi.nlm.nih.gov/pubmed/19826128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6150
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados